Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by PoorOpinionon Oct 02, 2018 9:25am

123 Views

Post# 28727973

RE:Canaccord Upgrade

Any idea which "third-party data" he's talking about? Bloomberg? Taimed sales data? The other pharma sales product (forget the name)?

retiredcf wrote:
Seeing accelerated traction for its Trogarzo HIV medication, Canaccord Genuity analyst Dewey Steadman raised his rating for Theratechnologies Inc. (TH-T) to "buy" from "speculative buy."

"August third-party data indicates another strong month of growth in August for Theratechnolgies as Egrifta and Trogarzo posted double-digit revenue and volume gains," he said. "We see Thera as a unique commercial-stage infectious disease story with an established product in Egrifta kicking off cash while Trogarzo continues to gain traction as the only approved therapy for multi-drug resistant HIV-1 infections. In addition, we like the optionality associated with access to the TaiMed HIV pipeline and the upcoming launch of the more convenient format of the F4 Egrifta formulation."

Mr. Steadman bumped his target for the Montreal-based pharmaceutical company to $15 from $14.50. The average is $15.95.